Stay updated on GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedA new revision tag (v3.5.4) was added to the study history, replacing the previous v3.5.3 tag. This reflects an administrative update to the record history.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe page revision/version indicator was updated from v3.5.2 to v3.5.3 for the ClinicalTrials.gov record history interface.SummaryDifference0.1%

- Check39 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0 from the history page.SummaryDifference0.1%

- Check68 days agoChange DetectedThe page history now includes a new revision labeled v3.5.0 and removes the previous v3.4.3 entry.SummaryDifference0.1%

- Check82 days agoChange DetectedAdded revision v3.4.3 to the record history and removed revision v3.4.2.SummaryDifference0.1%

- Check104 days agoChange DetectedA new revision entry v3.4.2 was added and the previous revision v3.4.1 was removed in the page history. This is a metadata update to the history log and does not affect study data or page functionality.SummaryDifference0.1%

Stay in the know with updates to GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page.